ID CLB HC.PH.BIO.CLB
Develops drugs, biologics or cell and gene therapies with no approved product on the market (no revenue, or milestones only); such a developer is here, not in contract research.
Sector, group and industry above this class, as placed in the current release. The sector and the industry link to their companies.
Companies whose primary class this is. The sector and industry pages and the screener count them the same way.
| Company | Ticker | Country | Market cap | Filings |
|---|---|---|---|---|
| Nanexa AB | NANEXA | Sweden | $83.45M | 511 |
| FluoGuide A/S | FLUO | Denmark | $80.83M | 346 |
| Annovis Bio, Inc. | ANVS | United States of America | $79.13M | 311 |
| Clene Inc. | CLNN | United States of America | $64.07M | 714 |
| Rafael Holdings, Inc. | RFL | United States of America | $72.30M | 406 |
| Adicet Bio, Inc. | ACET | United States of America | $62.11M | 710 |
| InflaRx N.V. | IFRX | Netherlands | $60.13M | 316 |
| TScan Therapeutics, Inc. | TCRX | United States of America | $59.78M | 359 |
| Acrivon Therapeutics, Inc. | ACRV | United States of America | $84.75M | 360 |
| OnKure Therapeutics, Inc. | OKUR | United States of America | $169.26M | 405 |
| Mereo BioPharma Group plc | MREO | United Kingdom | $57.40M | 656 |
| Greenland Mines Ltd | KLTO | United States of America | $56.66M | 265 |
| PDS Biotechnology Corp | PDSB | United States of America | $59.16M | 808 |
| RenovoRx, Inc. | RNXT | United States of America | $39.33M | 307 |
| IMMUTEP Ltd | IMMP | United States of America | $53.28M | 733 |
| Instil Bio, Inc. | TIL | United States of America | $52.83M | 248 |
| OS Therapies Inc | OSTX | United States of America | $76.61M | 230 |
| MiNK Therapeutics, Inc. | INKT | United States of America | $50.98M | 273 |
| Theranexus | ALTHX | France | $50.97M | 314 |
| Entera Bio Ltd. | ENTX | Israel | $50.90M | 419 |
| Metagenomi Therapeutics, Inc. | MGX | United States of America | $47.81M | 166 |
| ACTUATE THERAPEUTICS, INC. | ACTU | United States of America | $36.37M | 183 |
| Xilio Therapeutics, Inc. | XLO | United States of America | $49.21M | 366 |
| IMPACT BIOMEDICAL INC. | IBO | United States of America | $48.44M | 132 |
| NutriBand Inc. | NTRB | United States of America | $43.52M | 262 |
| LAVA Therapeutics NV Delisted | LVTX | Netherlands | $45.77M | 162 |
| Vivoryon Therapeutics N.V. | VVY | Netherlands | $45.58M | 444 |
| Kezar Life Sciences, Inc. | KZR | United States of America | $45.40M | 487 |
| LISATA THERAPEUTICS, INC. | LSTA | United States of America | $30.32M | 1,467 |
| Estrella Immunopharma, Inc. | ESLA | United States of America | $42.29M | 253 |
| SCYNEXIS INC | SCYX | United States of America | $46.77M | 726 |
| Rallybio Corp | RLYB | United States of America | $90.89M | 303 |
| Edesa Biotech, Inc. | EDSA | Canada | $44.50M | 745 |
| ATOSSA THERAPEUTICS, INC. | ATOS | United States of America | $18.75M | 657 |
| Sernova Biotherapeutics Inc. | SVA | Canada | $38.00M | 549 |
| Damora Therapeutics, Inc. | DMRA | United States of America | $43.73M | 351 |
| GeneOne Life Science, Inc. | 011000 | South Korea | $6.44M | 1,374 |
| Aligos Therapeutics, Inc. | ALGS | United States of America | $42.51M | 355 |
| Faeth Therapeutics, Inc. | FTH | United States of America | $42.12M | 461 |
| Telomir Pharmaceuticals, Inc. | TELO | United States of America | $83.22M | 144 |
| MIRA PHARMACEUTICALS, INC. | MIRA | United States of America | $42.02M | 196 |
| POOLBEG PHARMA PLC | POLB | United Kingdom | $39.98M | 196 |
| VERU INC. | VERU | United States of America | $39.64M | 1,193 |
| TALPHERA, INC. | TLPH | United States of America | $40.22M | 901 |
| Werewolf Therapeutics, Inc. | HOWL | United States of America | $38.73M | 457 |
| Ascelia Pharma | ACE | Sweden | $38.15M | 410 |
| Incannex Healthcare Inc. | IXHL | United States of America | $39.48M | 263 |
| Radiopharm Theranostics Ltd | RADX | United States of America | $36.58M | 152 |
| Generation Bio Co. | GBIO | United States of America | $35.98M | 529 |
| NextCure, Inc. | NXTC | United States of America | $35.64M | 407 |
Other names for this activity, and where neighboring activities go instead.
preclinicaldrug developer
Research-led company whose approved medicines, which it discovered, are in one or two therapeutic areas; it moves to Branded Prescription Drugs only after two consecutive annual reports with approved products in three or more.
https://financialfilings.com/oics/CLB/
This page is keyed by the class ID CLB. IDs are assigned in v0.3 and freeze at v1.0; from then on an ID is never renamed or reused, and if the class moves in the tree, its ID and this URL stay the same.
Sign in or create a free account - no password needed.
By continuing, you agree to our Terms and Privacy Policy.